Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

MORPHOSYS : AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2011 | 07:35am CEST

MorphoSys AG / AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its AbD Serotec unit entered a research and supply agreement with the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (DFCI) in Boston. Dana-Farber is engaged in research activities within a project funded by the Defense Advanced Research Projects Agency (DARPA) of the United States Department of Defense, to develop transient immunity against life-threatening viral infections. AbD Serotec will provide the laboratory of Wayne Marasco, MD, PhD with research tools using its proprietary Slonomics technology platform. AbD Serotec will receive financial compensation and has preferred access to commercialization rights for products generated during the collaboration.

"We are delighted to provide a world-class research organization with innovative research tools. This alliance can lead to both short- and long-term value for AbD Serotec and the entire MorphoSys group in the infectious disease area," commented Dieter Feger, Senior Vice President and Head of AbD Serotec.

 

 

About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/:
http://www.morphosys.com/

 

 

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and Slonomics® are registered trademarks of MorphoSys; arYlaTM is a trademark of MorphoSys.

 

 

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

 

 

 

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

 

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

 

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

 

[email protected]:
mailto:[email protected]

 

Press Release:
http://hugin.info/130295/R/1533054/466934.pdf

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;





This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

HUG#1533054
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
05/24 MORPHOSYS AG : MorphoSys Announces That Its Licensee Janssen Reported Updates on..
05/24 DGAP-NEWS : MorphoSys Announces That Its Licensee Janssen Reported Updates on th..
05/24 MORPHOSYS AG : MorphoSys to Present at Three Upcoming Conferences
05/24 MORPHOSYS : to Present at Three Upcoming Conferences
05/24 DGAP-NEWS : MorphoSys to Present at Three Upcoming Conferences
05/19 MORPHOSYS AG : MorphoSys Announces First Results from Phase 1 Study with Lanthip..
05/19 MORPHOSYS : Announces First Results from Phase 1 Study with Lanthipeptide MOR107..
05/19 DGAP-NEWS : MorphoSys Announces First Results from Phase 1 Study with Lanthipept..
05/18 DGAP-DD : MorphoSys AG english
05/18 MORPHOSYS AG : MorphoSys to Present Clinical Data on Proprietary Programs at Upc..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/06 Morphosys' (MPSYF) CEO Simon Moroney on Q1 2017 Results - Earnings Call Trans..
05/06 MorphoSys AG 2017 Q1 - Results - Earnings Call Slides
05/03 MorphoSys AG reports Q1 results
03/09 MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2016 Results - Earnings Call Trans..
03/09 MorphoSys AG reports Q4 results
Advertisement
Financials (€)
Sales 2017 51,7 M
EBIT 2017 -45,6 M
Net income 2017 -48,2 M
Finance 2017 252 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 32,2x
EV / Sales 2018 36,6x
Capitalization 1 917 M
More Financials
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 68,6 €
Spread / Average Target 5,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG34.13%2 143
INCYTE CORPORATION38.04%27 518
QUINTILES IMS HOLDINGS..11.37%18 872
LONZA GROUP AG25.78%15 703
CELLTRION, INC.--.--%10 293
SEATTLE GENETICS, INC.25.11%9 358
More Results